Board approved audited standalone financial results for Q4 and FY ended March 31, 2026, reporting FY PAT of ₹1081.38 Cr.
Recommended final dividend of ₹5 per equity share for FY26, subject to shareholder approval at 36th AGM on August 14, 2026.
Appointed Chhajed Kedia & Associates as Internal Auditors and Krishna S. & Associates as Cost Auditors for FY 2026-27.
Statutory auditors issued unmodified opinion on financial results, with company operating in Pharmaceuticals and Renewable Energy segments.